Financial Counselors Inc. Reduces Stock Position in Solventum Co. (NYSE:SOLV)

Financial Counselors Inc. trimmed its position in Solventum Co. (NYSE:SOLV) by 17.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,905 shares of the company’s stock after selling 1,012 shares during the quarter. Financial Counselors Inc.’s holdings in Solventum were worth $342,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Davis Selected Advisers acquired a new stake in Solventum during the 2nd quarter valued at approximately $273,070,000. Nuance Investments LLC acquired a new position in Solventum during the second quarter valued at $115,829,000. Newport Trust Company LLC purchased a new stake in Solventum in the second quarter valued at $98,976,000. Baupost Group LLC MA acquired a new stake in Solventum during the 2nd quarter worth about $96,242,000. Finally, Trian Fund Management L.P. raised its stake in shares of Solventum by 32.9% during the 3rd quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock valued at $496,842,000 after buying an additional 1,765,676 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on SOLV shares. Piper Sandler boosted their price target on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a report on Friday, November 8th. The Goldman Sachs Group boosted their target price on shares of Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a research note on Monday, August 12th. BTIG Research started coverage on shares of Solventum in a research report on Thursday, September 5th. They set a “neutral” rating on the stock. Wolfe Research assumed coverage on shares of Solventum in a research report on Thursday, September 26th. They issued a “peer perform” rating for the company. Finally, Morgan Stanley lifted their price target on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, Solventum presently has an average rating of “Hold” and an average price target of $68.00.

Solventum Price Performance

NYSE:SOLV opened at $71.51 on Friday. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $96.05. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The company’s 50-day moving average price is $70.55 and its 200-day moving average price is $62.58.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.